Guggenheim began coverage on shares of Passage Bio (NASDAQ:ORIC) in a report released on Tuesday morning, BenzingaRatingsTable reports. The firm issued a buy rating and a $45.00 target price on the stock.

Shares of NASDAQ ORIC opened at $29.04 on Tuesday. Passage Bio has a one year low of $24.26 and a one year high of $34.70.

Passage Bio (NASDAQ:ORIC) last announced its quarterly earnings data on Wednesday, May 20th. The company reported ($4.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($4.20). As a group, equities research analysts anticipate that Passage Bio will post -1.77 earnings per share for the current fiscal year.

In other news, Director Orbimed Advisors Llc purchased 281,250 shares of the business’s stock in a transaction dated Friday, April 24th. The stock was bought at an average cost of $25.68 per share, with a total value of $7,222,500.00.

Passage Bio Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors.

Featured Story: Discount Rate

Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with's FREE daily email newsletter.